City
Epaper

Researchers develop fast, accurate, low-cost Covid-19 test

By IANS | Updated: August 29, 2020 18:04 IST

Beijing, Aug 29 Chinese researchers have developed a new low-cost diagnostic test for Covid-19 which quickly delivers accurate ...

Open in App

Beijing, Aug 29 Chinese researchers have developed a new low-cost diagnostic test for Covid-19 which quickly delivers accurate results without the need for sophisticated equipment.

"In this study, we developed an isothermal, CRISPR-based diagnostic for Covid-19 with near single-copy sensitivity," the study authors from Xuzhou Medical University in China, wrote in a paper published in the journal PLOS Pathogens.

"We demonstrated a CRISPR-based assay for Covid-19 that offered shorter turn-around time and great diagnostic value, even in under-resourced settings without the need for thermal cyclers," they added.

The surging demand for rapid screening and identification of Covid-19 poses great diagnostic challenges.

Metagenomic next-generation sequencing (mNGS) and reverse-transcription PCR (RT-PCR) have been the most commonly used molecular methods for diagnosing Covid-19, but each has its own limitations.

For example, sequencing is costly and has a turnaround time of nearly one day, while RT-PCR requires specialized equipment and is difficult to deploy at a large scale.

According to the researchers, a lack of rapid and accurate molecular diagnostic tools has hampered efficient public health responses to the viral threat.

In the new study, the researchers developed an alternative Covid-19 test by leveraging CRISPR-based technology, which has been widely used in recent years for gene editing.

The assay, named CRISPR-COVID, enables high-throughput detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the virus that causes Covid-19.

CRISPR-COVID delivers comparable sensitivity and specificity as mNGS within as short as 40 minutes, the researchers said.

When produced at a large scale, the material cost of a CRISPR-COVID test could be less than 70 cents, suggesting that CRISPR-COVID is a competitive alternative not only technologically but also financially, the team noted.

( With inputs from IANS )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Xuzhou Medical UniversityPlos pathogenschinabeijing
Open in App

Related Stories

InternationalChina Blast: 17 Inured as Explosion Rocks Residential Area in Shanxi Province; Disturbing Video Goes Viral

BusinessGlobal Tech Firms Eye India for Manufacturing Amid US-China Tensions

OpinionsWill the Trump Card work Against China?

International20 Dead After Fire Blows Up A Nursing Home In Northern China (Photos)

InternationalUS Imposes 104% Tariff on China, Effective April 9

Health Realted Stories

HealthKozhikode hospital incident should not have happened: CM Vijayan

HealthDigital Common Services Centres bridging urban-rural divide through tech: Centre

HealthGene-editing therapy shows promise against advanced colorectal cancer

HealthOver 900 measles cases reported in US so far in 2025: CDC

HealthTN Health Department launches study on fatty liver disease among tribal communities